Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection. We resubmitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). The FDA has assigned a PDUFA date of June 19,2020 for CONTEPO. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Wednesday December 4, 2019 4:30 PM EST
Piper Jaffray Healthcare Conference

Tuesday November 12, 2019 4:30 PM EST
Nabriva Third Quarter 2019 Financial Results Call

Wednesday October 2, 2019 1:50 PM EDT
2019 Cantor Global Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View

Annual report which provides a comprehensive overview of the company for the past year

10-K
Annual Filings
View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Annual report which provides a comprehensive overview of the company for the past year

10-K
Annual Filings
View HTML EX-101.INS - EX-101.INS

Annual report which provides a comprehensive overview of the company for the past year

10-K
Annual Filings
View HTML EX-101.INS - EX-101.INS

Investor Contacts

E-mail: IR@nabriva.com